Ask Warren

Samsung Biologics

207940 · KOSPI · ₩SBL · 삼성바이오로직스

₩1,487,000▲ ₩121,000 (8.86%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩1.3T₩1.3T₩309B₩1.7T₩1.3T₩1.3T₩1.3T₩1.2T
Cost of sales₩621B₩577B₩223B₩681B₩571B₩565B₩588B₩643B
Gross profit₩700B₩680B₩86B₩979B₩719B₩733B₩669B₩544B
Operating income₩586B₩581B₩378B₩729B₩476B₩487B₩326B₩339B
Net income₩431B₩469B₩510B₩574B₩324B₩376B₩321B₩264B
Net income to shareholders₩431B₩469B₩510B₩574B₩324B₩376B₩321B₩264B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩13T₩12T₩11T₩18T₩18T₩17T₩17T₩16T
Current assets₩5.3T₩4.7T₩4.4T₩6.4T₩5.7T₩5.3T₩5.5T₩4.8T
Cash and equivalents₩289B₩520B₩149B₩922B₩709B₩752B₩391B₩540B
Total liabilities₩4.3T₩4.1T₩3.6T₩6.2T₩6.2T₩6.2T₩6.4T₩5.4T
Current liabilities₩3T₩2.7T₩2.5T₩3.8T₩3.6T₩3.6T₩3.9T₩3.6T
Borrowings₩965B₩919B₩919B₩1.2T₩1.3T₩1.3T₩1.3T₩822B
Total equity₩8.4T₩7.9T₩7.5T₩12T₩12T₩11T₩11T₩11T
Shareholders' equity₩8.4T₩7.9T₩7.5T₩12T₩12T₩11T₩11T₩11T

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩625B₩768B₩422B₩619B₩523B₩683B₩390B₩740B
Capital spending₩87B₩85B₩540B₩93B₩135B₩624B₩572B₩549B
Free cash flow₩537B₩683B−₩118B₩526B₩389B₩59B−₩182B₩191B

Consolidated where available. Amounts in won.

Also known as: Samsung Biologics / 삼성바이오로직스 / 207940 / KRX:207940

Source: KRX statistical information